Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

For all but the TNFi and IL-1 blocking agents, there are too few data to draw any conclusions. Since a lack of association is extremely difficult to prove, no biological agents can be assumed to be safe. Other biological agents Alefacept Alefacept (approved in the USA for psoriasis but not PsA) is a fully human fusion protein that blocks interaction between lymphocyte function-associated antigen-3 on antigen-presenting cells and CD2 on T cells, leading to decreased T cell activation and deletion of certain T cell clones.